Actively Recruiting

Phase 1
Age: 8Years - 18Years
All Genders
NCT06222034

Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

Led by Alfasigma S.p.A. · Updated on 2025-12-10

10

Participants Needed

10

Research Sites

115 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A Study to evaluate the pharmacokinetics, safety, and tolerability in paediatric population for treating juvenile idiopathic arthritis (JIA).

CONDITIONS

Official Title

Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

Who Can Participate

Age: 8Years - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant aged 8 to less than 18 years
  • Body mass index (BMI) within the 5th to 95th percentile for age and gender
  • Minimum body weight of 15 kg
  • Diagnosed with juvenile idiopathic arthritis according to International League of Associations for Rheumatology criteria, including categories like rheumatoid factor-positive or negative polyarthritis, oligoarthritis, psoriatic arthritis, enthesis-related arthritis, or systemic JIA with stable systemic features
  • Moderately to severely active disease not adequately controlled by current therapy
  • History of intolerance or inadequate response to at least one JIA medication such as methotrexate or biological disease-modifying antirheumatic drugs for at least 12 weeks
  • Female participants of childbearing potential must have a negative pregnancy test
Not Eligible

You will not qualify if you...

  • Persistent oligoarthritis
  • Undifferentiated arthritis
  • Other rheumatic, inflammatory, or immunologic diseases such as inflammatory bowel disease, hypogammaglobulinemia, systemic lupus erythematosus, or uncontrolled uveitis
  • Clinically significant active infection
  • History of complicated herpes zoster infection involving multiple areas or central nervous system
  • Currently receiving therapy for chronic infections like pneumocystis, cytomegalovirus, herpes simplex, or atypical mycobacteria
  • Other protocol-defined exclusion criteria may apply

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 10 locations

1

CHU Amiens - Hopital Nord

Amiens, France, 80054

Actively Recruiting

2

Bicêtre University Hospital

Le Kremlin-Bicêtre, France, 94270

Actively Recruiting

3

Children's university hospital Charité, Campus Virchow, SPZ

Berlin, Germany, 13353

Actively Recruiting

4

Hamburger Zentrum fur Kinder und Jugendrheumatologie

Hamburg, Germany, 22081

Actively Recruiting

5

Asklepios Klinik Sankt Augustin GmbH

Sankt Augustin, Germany, 53757

Not Yet Recruiting

6

Malopolskie Badania Kliniczne

Krakow, Poland, 30-002

Actively Recruiting

7

Hospital Universitari Vall d'Hebron

Barcelona, Spain, 08035

Actively Recruiting

8

Hospital Sant Joan de Deu

Barcelona, Spain, 08950

Actively Recruiting

9

Hospital Universitari i Politecnic La Fe

Valencia, Spain, 46026

Actively Recruiting

10

Great Ormond Street Hospital

London, United Kingdom, WC1N 3JH

Not Yet Recruiting

Loading map...

Research Team

P

Pilar de la Torre

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here